OverviewSuggest Edit

Agendia offers discovery, development, marketing, and commercialization of genomic-based diagnostic products to improve the quality of life for cancer patients by providing healthcare professionals with critical information to enable personalized treatment. It offers Symphony suite of molecular diagnostic breast cancer tests, such as TargetPrint, a microarray-based gene expression assay, which offers a quantitative assessment of the patient’s level of estrogen receptor, progesterone receptor, and HER2/neu gene within breast cancer tumor; and MammaPrint, a IVDMIA gene expression breast cancer assay that provides physicians with the ability to identify which early-stage breast cancer patients are at risk of distant recurrence following surgery.

HQIrvine, CA, US
Employee Ratings3.3

Latest Updates

Employees (est.) (Jan 2021)218
Cybersecurity ratingAMore

Key People/Management at Agendia

Mark R. Straley

Mark R. Straley

Chief Executive Officer
Kurt Becker

Kurt Becker

Chief Financial Officer (CFO) & Chief Operations Officer (COO)
William Audeh

William Audeh

Chief Medical Officer (CMO)
Wendy Blosser

Wendy Blosser

Chief Commercial Officer
Laura van 't Veer

Laura van 't Veer

Chief Research Officer (CRO) and Co‑founder
Patrick J. Balthrop

Patrick J. Balthrop

Show more

Agendia Office Locations

Agendia has offices in Irvine and Amsterdam
Irvine, CA, US (HQ)
22 Morgan
Amsterdam, NL
Radarweg 60
Show all (2)

Agendia Financials and Metrics

Summary Metrics

Founding Date


Agendia total Funding

$122 m

Agendia latest funding size

$65 m

Time since last funding

9 years ago

Agendia investors

Agendia's latest funding round in March 2012 was reported to be $65 m. In total, Agendia has raised $122 m
Show all financial metrics

Agendia Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Agendia Online and Social Media Presence

Embed Graph

Agendia News and Updates

Agendia to Participate in Stifel 2020 Virtual Healthcare Conference

IRVINE, Calif., Oct. 15, 2020 /PRNewswire/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the 2020 Stifel Virtual Healthcare Conference, which takes place November 16-18, 2020. Agendia Chief Executive Mark Straley will...

Agendia, HiSS Diagnostics and PathoNext offer local MammaPrint and BluePrint testing for breast cancer patients in Germany

IRVINE, Calif., Oct. 6, 2020 /PRNewswire/ -- Agendia Inc., a world leader in precision oncology for breast cancer, announced today the availability of local testing for its CE-marked MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping tests, provided by PathoNext lab...

Agendia présente de nouvelles données démontrant l'utilité clinique de MammaPrint et BluePrint lors de l'événement virtuel de la Conférence européenne sur le cancer du sein 2020

Présentations incluant les données de l'étude MINDACT de suivi et des évaluations sur l'utilisation de MammaPrint pour guider les décisions de traitement concernant les cancers lobulaires et pour les cancers du sein détectés par dépistage par rapport aux cancers du sein détectés par...

Agendia Presents New Data Demonstrating MammaPrint's Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients at the European Society for Medical Oncology Virtual Congress

IRVINE, Calif., Sept. 17, 2020 /PRNewswire/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, today presented data at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 showing that MammaPrint's Ultra-Low risk threshold can identify...

Agendia Publishes Unprecedented Full Genome Dataset from MINDACT Trial for the Advancement of Translational Research in Communications Biology

IRVINE, Calif., July 27, 2020 /PRNewswire/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, today announced the publication of MINDACT trial data in the July 27 issue of Communications Biology, a Nature Publishers Journal. In the largest data set seen to date, the...

Agendia to Present New Data at SABCS 2019 Demonstrating How Comprehensive Genomic Profiling Benefits Early-Stage Breast Cancer Patients

IRVINE, Calif., Nov. 19, 2019 /PRNewswire/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that five abstracts featuring data and updates from its ongoing clinical research evaluating the MammaPrint® and BluePrint® genomic tests have been accepted...
Show more

Agendia Blogs

Agendia to Participate in the 39th Annual J.P. Morgan Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the 39th Annual J.P. Morgan Healthcare Conference, which will take place from Monday, January 11 through Thursday, January 14, 2021. Agendia Chief Executive Ma…

Racial disparities within Basal-type breast cancer: clinical and molecular features of African American and Caucasian obese patients

PUBLICATION: SABCS 2020 AUTHORS: Dipali Sharma, Lisa E. Blumencranz, Heather M. Kling, Sahra Uygun, Sarah Untch, William Audeh, Jennifer A. Crozier, Mehran Habibi, and Raquel Nunes1 Background: African American breast cancer (BC) patients (AA) are diagnosed at a younger age and present more frequent…

Molecular profiles and clinical-pathological features of Asian early-stage breast cancer patients

PUBLICATION: SABCS 2020 AUTHORS: Margaret Chen, Ava Kwong, Carolyn Hendricks, Nina D'Abreo, Laura Lee, Hatem H. Soliman, Charles Cox, Heather M. Kling, Midas M. Kuilman, Rajith Bhaskaran, Shiyu Wang, Andrea Menicucci, Sarah Untch, William Audeh, FLEX Investigators Group Background: Breast cancer inc…

Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens

PUBLICATION: SABCS 2020 AUTHORS: Joseph McKelley, Jennifer Wei, Brian Hoxeng, Andrea Menicucci, Erin Yoder, Shiyu Wang, William Audeh Background: Pre-operative/neoadjuvant treatment utilization in early-stage breast cancer has been increasing, particularly during the COVID-19 pandemic. With goals of…

MammaPrint and BluePrint as prognostic indicators for elderly patients with early-stage breast cancer

PUBLICATION: SABCS 2020 AUTHORS: Peter W. Blumencranz, Mehran Habibi, Lisa Blumencranz, Andrea Menicucci, Shiyu Wang, Amy Truitt, William Audeh, Jolanta L. Baginski, Steven Shivers, Geza Acs, Charles E. Cox, MINT Investigators Group. Background: Elderly breast cancer (BC) patients are an understudie…

Differential gene expression in Luminal type invasive lobular carcinoma and invasive ductal carcinoma by MammaPrint risk stratification

PUBLICATION: SABCS 2020 AUTHORS: Beth-Ann Lesnikoski, Jennifer A. Crozier, Gordan Srkalovic, Patricia Robinson, Clodia Osipo, Kalyan Banda, Heather M. Kling, Midas M. Kuilman, Josien Haan, William Audeh, and FLEX Investigators Group Background: Invasive lobular carcinoma (ILC) comprises 10-15% of br…
Show more

Agendia Frequently Asked Questions

  • When was Agendia founded?

    Agendia was founded in 2003.

  • Who are Agendia key executives?

    Agendia's key executives are Mark R. Straley, Kurt Becker and William Audeh.

  • How many employees does Agendia have?

    Agendia has 218 employees.

  • Who are Agendia competitors?

    Competitors of Agendia include VERTIS Biotechnologie, CS Genetics and KBioBox.

  • Where is Agendia headquarters?

    Agendia headquarters is located at 22 Morgan, Irvine.

  • Where are Agendia offices?

    Agendia has offices in Irvine and Amsterdam.

  • How many offices does Agendia have?

    Agendia has 2 offices.